Effect of intra-amygdala injection of nicotine and GABA receptor agents on anxiety-like behaviour in rats

Pharmacology

Volumn 82, Issue 4, 2008, Pages 276-284

  Zarrindast, Mohammad Reza ^a,b,c   Solati, Jalal ^c,d   Oryan, Shahrbanoo ^c   Parivar, Kazem ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b INSTITUTE FOR STUDIES IN THEORETICAL PHYSICS AND MATHEMATICS IPM   (Iran)

^c KHARAZMI UNIVERSITY   (Iran)

^d ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

Amygdala, rat; Anxiety; GABAergic agents; Nicotinic agents

Indexed keywords

3 AMINOPROPYL(DIETHOXYMETHYL)PHOSPHINIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR; BACLOFEN; BICUCULLINE; MECAMYLAMINE; MUSCIMOL; NICOTINE; NICOTINIC RECEPTOR; SODIUM CHLORIDE;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANXIETY; ARTICLE; CHOLINERGIC SYSTEM; CONTROLLED STUDY; DRUG EFFECT; DRUG RECEPTOR BINDING; GABAERGIC SYSTEM; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; RAT;

AMYGDALA; ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; BICUCULLINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GABA AGONISTS; GABA ANTAGONISTS; MALE; MAZE LEARNING; MECAMYLAMINE; MOTOR ACTIVITY; MUSCIMOL; NICOTINE; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; RATS; RATS, WISTAR; RECEPTORS, GABA-A; RECEPTORS, NICOTINIC;

EID: 53449101793     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000161129     Document Type: Article

References (70)

1. Bueno CH, Zangrossi H Jr, Viana MB: The inactivation of the basolateral nucleus of the rat amygdala has an anxiolytic effect in the elevated t-maze and light/dark transition tests. Braz J Med Biol Res 2005;38:1697-1701.
2. LeDoux J: The emotional brain, fear, and the amygdala. Cell Mol Neurobiol 2003;23:727-738.
3. Walker DL, Toufexis DJ, Davis M: Role of the bed nucleus of the stria terminalis versus the amygdala in fear, stress, and anxiety. Eur J Pharmacol 2003;463:199-216.
4. Davis M: The role of the amygdala in conditioned and unconditioned fear and anxiety; in Aggleton JP (ed): The Amygdala. New York, Oxford University Press, 2000.
5. Fendt M, Fanselow MS: The neuroanatomical and neurochemical basis of conditioned fear. Neurosci Biobehav Rev 1999;23:743-760.
6. LeDoux J: The amygdala and emotion: a view through fear; in Aggleton JP (ed): The Amygdala. New York, Oxford University Press, 2000, pp 289-310.
7. Alheid G, Olmos JS, Beltramino CA: Amygdala and extended amygdala; in Paxinos G (ed): The Rat Nervous System. New York, Academic Press, 1995.
8. Wilensky AE, Schafe GE, Kristensen MP, LeDoux JE: Rethinking the fear circuit: the central nucleus of the amygdala is required for the acquisition, consolidation, and expression of pavlovian fear conditioning. J Neurosci 2006;26:12387-12396.
9. Davis M, Shi C: The extended amygdala: are the central nucleus of the amygdala and the bed nucleus of the stria terminalis differentially involved in fear versus anxiety? Ann NY Acad Sci 1999;877:281-291.
10. Moreira CM, Masson S, Carvalho MC, Brandao ML: Exploratory behaviour of rats in the elevated plus-maze is differentially sensitive to inactivation of the basolateral and central amygdaloid nuclei. Brain Res Bull 2007;71:466-474.
11. Zarrindast MR, Fattahi Z, Rostami P, Rezayof A: Role of the cholinergic system in the rat basolateral amygdala on morphine-induced conditioned place preference. Pharmacol Biochem Behav 2005;82:1-10.
12. Degroot A, Treit D: Dorsal and ventral hippocampal cholinergic systems modulate anxiety in the plus-maze and shock-probe tests. Brain Res 2002;949:60-70.
13. Degroot A, Treit D: Septal gabaergic and hippocampal cholinergic systems interact in the modulation of anxiety. Neuroscience 2003;117:493-501.
14. Irvine EE, Cheeta S, File SE: Tolerance to nicotine's effects in the elevated plus-maze and increased anxiety during withdrawal. Pharmacol Biochem Behav 2001;68:319-325.
15. Ouagazzal AM, Kenny PJ, File SE: Modulation of behaviour on trials 1 and 2 in the elevated plus-maze test of anxiety after systemic and hippocampal administration of nicotine. Psychopharmacology (Berl) 1999;144:54-60.
16. File SE, Kenny PJ, Ouagazzal AM: Bimodal modulation by nicotine of anxiety in the social interaction test: role of the dorsal hippocampus. Behav Neurosci 1998;112:1423-1429.
17. Brioni JD, O'Neill AB, Kim DJ, Decker MW: Nicotinic receptor agonists exhibit anxiolytic-like effects on the elevated plus-maze test. Eur J Pharmacol 1993;238:1-8.
18. Cao W, Burkholder T, Wilkins L, Collins AC: A genetic comparison of behavioral actions of ethanol and nicotine in the mirrored chamber. Pharmacol Biochem Behav 1993;45:803-809.
19. Costall B, Kelly ME, Naylor RJ, Onaivi ES: The actions of nicotine and cocaine in a mouse model of anxiety. Pharmacol Biochem Behav 1989;33:197-203.
20. Vale AL, Green S: Effects of chlordiazepoxide, nicotine and D-amphetamine in the rat potentiated startle model of anxiety. Behav Pharmacol 1996;7:138-143.
21. Zarrindast MR, Homayoun H, Babaie A, Etminani A, Gharib B: Involvement of adrenergic and cholinergic systems in nicotine-induced anxiogenesis in mice. Eur J Pharmacol 2000;407:145-158.
22. O'Neill AB, Brioni JD: Benzodiazepine receptor mediation of the anxiolytic-like effect of (-)-nicotine in mice. Pharmacol Biochem Behav 1994;49:755-757.
23. Fuxe K, Andersson K, Harfstrand A, Eneroth P, Mora M, Agnati LF: Effects of nicotine on synaptic transmission in the brain; in Wonnacott S, Russell MAH, Stolerman IP (eds): Nicotine Psychopharmacology: Molecular, Cellular and Behavioural Aspects. Oxford, Oxford University Press, 1990, pp 194-225.
24. Balfour DJK: The neurochemical mechanisms underlying nicotine tolerance and dependence; in Pratt JA (ed): The Biological Bases of Drug Tolerance and Dependence. New York, Academic Press, 1991.
25. 1 receptors. Neuropharmacology 2000;39:300-307.
26. Cheeta S, Irvine E, File SE: Social isolation modifies nicotine's effects in animal tests of anxiety. Br J Pharmacol 2001;132:1389-1395.
27. Summers KL, Giacobini E: Effects of local and repeated systemic administration of (-)nicotine on extracellular levels of acetylcholine, norepinephrine, dopamine, and serotonin in rat cortex. Neurochem Res 1995;20:753-759.
28. Oksztel R, Car H, Wisniewski K: Muscimol changes hypoxia-induced impairment of behavior in rats. Pol J Pharmacol 2002;54:423-431.
29. Chebib M, Johnston GA: The 'ABC' of GABA receptors: a brief review. Clin Exp Pharmacol Physiol 1999;26:937-940.
30. Johnston GA: Rand lecture, ascept. GABA receptors: as complex as ABC? Australasian Society for Clinical and Experimental Pharmacologists and Toxicologists. Clin Exp Pharmacol Physiol 1994;21:521-526.
31. A receptor function in rat brain. J Neurochem 2000;75:732-740.
32. A and 5-HT anxiolytics. Psychopharmacology (Berl) 1995;121:38-56.
33. A receptor in the amygdala after progesterone withdrawal. Eur J Neurosci 2003;17:641-648.
34. 3H] muscimol binding: pharmacological correlation, and multifactor analysis. Behav Brain Res 2003;145:17-22.
35. Plaznik A, Kostowski W, Stefanski R: Limbic mechanisms of anxiolytics acting on 5-HT receptors. Pol J Pharmacol 1994;46:473-477.
36. A receptor subtypes: dissecting their pharmacological functions. Trends Pharmacol Sci 2001;22:188-194.
37. 3 receptor antagonists. Neuropharmacology 1993;32:987-993.
38. 1A receptor agonists. Neuropharmacology 1993;32:977-985.
39. Davis M: The role of the amygdala in fear and anxiety. Annu Rev Neurosci 1992;15:353-375.
40. McNaughton N, Gray JA: Anxiolytic action on the behavioural inhibition system implies multiple types of arousal contribute to anxiety. J Affect Disord 2000;61:161-176.
41. Ferkany JW, Enna SJ: Interaction between GABA agonists and the cholinergic muscarinic system in rat corpus striatum. Life Sci 1980;27:143-149.
42. Xi MC, Morales FR, Chase MH: Interactions between GABAergic and cholinergic processes in the nucleus pontis oralis: neuronal mechanisms controlling active (rapid eye movement) sleep and wakefulness. J Neurosci 2004;24:10670-10678.
43. Mallick BN, Kaur S, Saxena RN: Interactions between cholinergic and GABAergic neurotransmitters in and around the locus coeruleus for the induction and maintenance of rapid eye movement sleep in rats. Neuroscience 2001;104:467-485.
44. Barazangi N, Role LW: Nicotine-induced enhancement of glutamatergic and GABAergic synaptic transmission in the mouse amygdala. J Neurophysiol 2001;86:463-474.
45. Paxinos G, Watson C: The Rat Brain in Stereotaxic Coordinates. Sydney, Academic Press, 1986.
46. Degroot A, Kashluba S, Treit D: Septal GABAergic and hippocampal cholinergic systems modulate anxiety in the plus-maze and shock-probe tests. Pharmacol Biochem Behav 2001;69:391-399.
47. Pellow S, Chopin P, File SE, Briley M: Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 1985;14:149-167.
48. Pellow S: Anxiolytic and anxiogenic drug effects in a novel test of anxiety: are exploratory models of anxiety in rodents valid? Methods Find Exp Clin Pharmacol 1986;8:557-565.
49. Rodgers RJ, Johnson NJ: Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety. Pharmacol Biochem Behav 1995;52:297-303.
50. LeDoux J: Fear and the brain: where have we been, and where are we going? Biol Psychiatry 1998;44:1229-1238.
51. Henke PG, Ray A: Stress ulcer modulation by limbic system structures. Acta Physiol Hung 1992;80:117-125.
52. Feldman S, Weidenfeld J: The excitatory effects of the amygdala on hypothalamo-pituitary-adrenocortical responses are mediated by hypothalamic norepinephrine, serotonin, and CRF-41. Brain Res Bull 1998;45:389-393.
53. Goldstein LE, Rasmusson AM, Bunney BS, Roth RH: Role of the amygdala in the coordination of behavioral, neuroendocrine, and prefrontal cortical monoamine responses to psychological stress in the rat. J Neurosci 1996;16:4787-4798.
54. Moller C, Wiklund L, Sommer W, Thorsell A, Heilig M: Decreased experimental anxiety and voluntary ethanol consumption in rats following central but not basolateral amygdala lesions. Brain Res 1997;760:94-101.
55. Khoshbouei H, Cecchi M, Dove S, Javors M, Morilak DA: Behavioral reactivity to stress: amplification of stress-induced noradrenergic activation elicits a galanin-mediated anxiolytic effect in central amygdala. Pharmacol Biochem Behav 2002;71:407-417.
56. Umezu T: Effects of psychoactive drugs in the Vogel conflict test in mice. Jpn J Pharmacol 1999;80:111-118.
57. Picciotto MR, Brunzell DH, Caldarone BJ: Effect of nicotine and nicotinic receptors on anxiety and depression. Neuroreport 2002;13:1097-1106.
58. Newman MB, Manresa JJ, Sanberg PR, Shytle RD: Anxiolytic effects of mecamylamine in two animal models of anxiety. Exp Clin Psychopharmacol 2002;10:18-25.
59. Newman MB, Nazian SJ, Sanberg PR, Diamond DM, Shytle RD: Corticosterone-attenuating and anxiolytic properties of mecamylamine in the rat. Prog Neuropsycho pharmacol Biol Psychiatry 2001;25:609-620.
60. File SE, Kenny PJ, Cheeta S: The role of the dorsal hippocampal serotonergic and cholinergic systems in the modulation of anxiety. Pharmacol Biochem Behav 2000;66:65-72.
61. Balerio GN, Aso E, Maldonado R: Involvement of the opioid system in the effects induced by nicotine on anxiety-like behaviour in mice. Psychopharmacology (Berl) 2005;181:260-269.
62. Mansour A, Fox CA, Akil H, Watson SJ: Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci 1995;18:22-29.
63. A receptor complex ligands in two models of anxiety. J Neural Transm 1997;104:733-746.
64. File SE: Animal models for predicting clinical efficacy of anxiolytic drugs: social behaviour. Neuropsychobiology 1985;13:55-62.
65. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther 2002;300:2-8.
66. Whiting P, Wafford K, McKernan RM: Pharmacologic subtypes of receptors based on subunit composition; in Martin D, Olsen RW (eds): GABA in the Nervous System: The View at Fifty Years. Philadelphia, Lippincott Williams & Wilkins, 2000.
67. A receptors. Eur J Pharmacol 1997;325:1-7.
68. A receptors. Prog Neurobiol 2002;67:113-159.
69. A receptors. Brain Res Brain Res Rev 1999;29:196-217.
70. Millan MJ: The neurobiology and control of anxious states. Prog Neurobiol 2003;70:83-244.